CLL cells, which expressed low levels of BCMA could be efficiently targeted by teclistamab, providing proof of principle that BCMA-directed therapies might be beneficial for other B-cell malignancy patients besides multiple myeloma. The gene discussed is TNFRSF17; the disease is AL amyloidosis.